Center-Authored Papers

Filters: Author is Soria, Jean-Charles  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Treatment Outcome
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Survival Rate
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Receptor, erbB-2
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Receptor, Epidermal Growth Factor
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Quinolines
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Public Health Sciences Division
Ferté C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C et al..  2014.  Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(1):246-52. Abstract
Guinney J, Ferté C, Dry J, McEwen R, Manceau G, Kao KJ, Chang K-M, Bendtsen C, Hudson K, Huang E et al..  2014.  Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(1):265-72. Abstract
Ferté C, Koscielny S, Albiges L, Rocher L, Soria J-C, Iacovelli R, Loriot Y, Fizazi K, Escudier B.  2014.  Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.. European urology. 65(4):713-20. Abstract
Prospective Studies
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Mutation
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Middle Aged
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Male
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Lung Neoplasms
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
International Agencies
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Humans
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Female
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
February 2014
Guinney J, Ferté C, Dry J, McEwen R, Manceau G, Kao KJ, Chang K-M, Bendtsen C, Hudson K, Huang E et al..  2014.  Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(1):265-72. Abstract
Ferté C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C et al..  2014.  Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(1):246-52. Abstract
Carcinoma, Non-Small-Cell Lung
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
April 2014
Ferté C, Koscielny S, Albiges L, Rocher L, Soria J-C, Iacovelli R, Loriot Y, Fizazi K, Escudier B.  2014.  Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.. European urology. 65(4):713-20. Abstract
Aged, 80 and over
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Aged
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
Adult
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract
ADENOCARCINOMA
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton KD, Zacharchuk C, Freyman A, Powell C et al..  2010.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3076-83. Abstract